New Academic Research Collaboration (ARC) program makes cutting-edge nanomaterials processing equipment more accessible and valuable
Newton, MA (PRWEB) May 17, 2010 — Microfluidics (OTCBB: MFLU), the exclusive global provider of Microfluidizer(R) high shear fluid processors, has initiated a formal collaboration program to further promote the use of nanotechnology in scientific research at the university level. Microfluidizer processors are currently used by hundreds of leading academic institutions to develop breakthrough drug delivery technologies and tailor novel applications for the nutraceutical/food, chemical, energy and cosmetic industries.
University researchers who would like to learn more about the program should visitwww.microfluidicscorp.com/academics.
Microfluidizer technology is unique in its ability to achieve uniform target particle sizes on the nano-level with fully scalable results from lab to production volumes. The Academic Research Collaboration (ARC) program was created to make superior nanomaterials processing methods more accessible to a wider range of academic initiatives while providing further value to facilitate research and development efforts:
“Partnering with Microfluidics has enabled us to advance exciting new nanotechnology-based methods for drug delivery, for example, to penetrate the blood brain barrier,” said Mansoor Amiji, Ph.D., Distinguished Professor and Chair of Pharmaceutical Sciences at Northeastern University. “This is the only technology successful thus far in creating decorated drug nanoparticles which deliver benefits to specific parts of the body and, therefore, accomplish more with less drug.”
“As you reduce the particle size of your formulation containing the compound of interest, you increase its surface area, thereby improving bioavailability and efficacy and, as a result, reducing adverse side effects by decreasing the required dose for effectiveness,” explained Prof. Robert Nicolosi, Ph.D., of the Department of Clinical Laboratory & Nutritional Sciences at University of Massachusetts Lowell. “Microfluidics provides an enabling technology which has allowed us to develop novel properties for pharmaceutical, nutraceutical and cosmeceutical applications.”
More than one in every ten Microfluidizer processors sold are to universities – a figure Microfluidics expects to increase over time as the core model for biopharmaceutical R&D continues to evolve. The recently launched LV1 low volume processor, which for the first time brings Microfluidizer-quality processing capabilities to samples as small as 1 ml, is an ideal solution for universities with limited or high value raw materials.
“The importance of academic research to the pharmaceutical industry’s drug development strategy cannot be understated, and it’s increasing every day,” said Michael C. Ferrara, Microfluidics President and CEO. “More big and mid-size pharmas are seeking to collaborate on vital R&D programs with universities equipped with the latest equipment for nanomaterials processing. From oncology drugs and vaccines, to foods enhanced with nutrients and more efficient cathodes for fuel and solar cells, the line between academic research and industry commercialization has been blurred. By bringing our gold standard nanomaterial processors more actively to the university level, we are able to improve our customers’ business lines while supporting the crucial growth and innovation indicative of expert professors and graduate students worldwide.”
In addition, existing collaborations with universities have led to revolutions in what is possible using nanotechnology. Continuous manufacturing via crystallization and chemical reactions using bottom-up Microfluidics Reaction Technology(TM) (MRT), for example, was developed in a partnership between Microfluidics CTO Thomai “Mimi” Panagiotou, Ph.D., and Robert Fisher, Ph.D., of the Chemical Engineering Department at the Massachusetts Institute of Technology.
Said Dr. Fisher, “I was intrigued by the opportunity to work closely with Microfluidics to develop improved drug fabrication techniques that enhance delivery and efficacy, which pharmaceutical firms will find extremely compelling. This includes producing suspensions with the smallest possible particle size that have been functionalized for specific targeting.”
More information on the ARC program can be found on http://ww.microfluidicscorp.com/academics or by contacting Kris Sarajian at (+1) 617.969.5454 x233.
ABOUT MICROFLUIDICS Microfluidics International Corporation (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company’s headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.
By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visitwww.microfluidicscorp.com.